Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge ABMIL:1GETI 52 EV-to-EBITDA is 11.12 as of Aug. 12, 2026, which is 1% above its 10-year median of 10.97. GuruFocus rates MIL:1GETI with a GF Score™ of 52/100 and a GF Value™ of €17.65 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Getinge AB ranks better than 63.69% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Getinge AB's enterprise value is €6,769 Mil.
Getinge AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €609 Mil. Therefore, Getinge AB's EV-to-EBITDA for today is 11.12.
The historical rank and industry rank for Getinge AB's EV-to-EBITDA or its related term are showing as below:
MIL:1GETI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.84 Med: 10.97 Max: 47.31
Current: 11.17
During the past 13 years, the highest EV-to-EBITDA of Getinge AB was 47.31. The lowest was 7.84. And the median was 10.97.
MIL:1GETI's EV-to-EBITDA is ranked better than 63.69% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.92
vs MIL:1GETI: 11.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Getinge AB's share price for today is €20.90.
Getinge AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Getinge AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1GETI vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Getinge AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getinge AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Getinge AB's EV-to-EBITDA falls into.
Getinge AB's current Enterprise Value is €6,769 Mil.
Getinge AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €609 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getinge AB (MIL:1GETI) has a EV-to-EBITDA of 11.12 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Getinge AB. This is near median its historical median of 10.97. Over the past decade, Getinge AB's EV-to-EBITDA has ranged from 7.84 to 47.31. According to the industry distribution chart, Getinge AB ranks #187 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 36.3%.
Is Getinge AB's EV-to-EBITDA too high?
Getinge AB's current EV-to-EBITDA of 11.12 is near median its 10-year median of 10.97. Over the past 10 years, this metric has ranged from a low of 7.84 to a high of 47.31. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.92. Getinge AB's value of 11.12 is 25.5% below this industry median. Based on the distribution chart, Getinge AB ranks #187 out of 515 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Getinge AB has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #187 out of 515 companies for EV-to-EBITDA. This puts Getinge AB in the upper half of its industry. The industry median EV-to-EBITDA is 14.92. Getinge AB's value of 11.12 is 25.5% below this benchmark. Historically, Getinge AB's own EV-to-EBITDA has ranged from 7.84 to 47.31 over the past decade. While the company's 10-year median is 10.97 vs. the industry median of 14.92, Getinge AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.92, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getinge AB's current EV-to-EBITDA of 11.12 is 25.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Getinge AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current EV-to-EBITDA is 11.12, which is near median its own 10-year median of 10.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (MIL:1GETI) is currently considered Modestly Overvalued. The stock's GF Value™ is €17.65, compared to a current price of €20.90 — trading 18.4% above its estimated fair value. The current EV-to-EBITDA is 11.12, which is near median its 10-year median of 10.97 and 25.5% below the Medical Devices & Instruments industry median of 14.92. Getinge AB's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Getinge AB (MIL:1GETI), the current EV-to-EBITDA is 11.12 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (MIL:1GETI) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of €20.90 is trading 18.4% above its estimated GF Value™ of €17.65.
GuruFocus considers Getinge AB to be Modestly Overvalued.
Key valuation signals for MIL:1GETI:
EV-to-EBITDA: 11.12 (near median its 10-year median of 10.97)
GF Value™: €17.65 vs. price of €20.90 (18.4% above fair value)
Industry Position: 25.5% below the Medical Devices & Instruments median (#187 of 515)
No single metric tells the full story. See the MIL:1GETI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
52GF Score
Get the complete analysis for MIL:1GETI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1GETI has been successfully added to your 
